Spirapril effects on heart remodeling in patients with mild to moderate arterial hypertension
Abstract
About the Authors
M. M. BerayaRussian Federation
V. V. Petriy
Russian Federation
V. I. Buvaltsev
Russian Federation
N. G. Sergushkina
Russian Federation
V. I. Makolkin
Russian Federation
References
1. Devereux R.B., Agabiti-Rosei E., Dahlof В. Regression of left ventricular hypertrophy as asurrogate end-point for morbid events in antihypertensive treatment trials. J Hypertens 1996, 14: S95-101.
2. Folkow B. Physiological aspects of primary hypertension. Physiol. Rev. 1982, 62: 347-504.
3. Guitard C., Sassano P. Placebo-controlled comparison of spirapril at 6 mg/day in mild vere essential hypertensio. Ibid. 61-68.
4. Lagagh G. Cardiac patophysiology and its heterogenety in patients with established hypertensive diasease. Am. J. Med. 1988; 84: 3-11.
5. Muiesan M.I., Salvetti M., Rizonni D. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J. Hypertens 1995, 13: 1091-1097.
6. Regression of cardiovascular structurial changes by antihypertensive treatment. Hypertension 1984, 6: 150-157.
7. Roman O., Bunout D., Prats H. Efficacy and safety of spirapril a new ACE ingibitor. A long term study on hypertensive patients. J. Hypertens. 1994; 12: 165.
8. Safar M.E., Laurent S.L., Bouthier J.D. Effect of converting enzyme ingnbitors on hypertensive lage arteries in humans. J. Hypertens. 1986; 5: S285-289.
9. Vedecchia P., Schfflaci G., Borgioni C. Prognostic significance of serial changes in left ventricular mass in essential hypertension//Circulation 1998; 97: 48-54.
Review
For citations:
Beraya M.M., Petriy V.V., Buvaltsev V.I., Sergushkina N.G., Makolkin V.I. Spirapril effects on heart remodeling in patients with mild to moderate arterial hypertension. Russian Journal of Cardiology. 2007;(1):45-47. (In Russ.)